Adults living with dermatomyositis now have a medicine approved specifically for their disease for the first time. The Food and Drug Administration approved Lisraya, known generically as brepocitinib, on August 27 as a once-daily 30 mg tablet for adults with a rare autoimmune condition that attacks the muscles and skin, causing progressive weakness and painful, itchy rashes.
The practical significance is what patients have been living without. For decades, treatment has meant chronic corticosteroids and drugs borrowed from other autoimmune conditions, none of them approved for dermatomyositis itself. That has left patients managing a debilitating disease with therapies never studied primarily for it, and often carrying the cumulative burden of long-term steroid use.
"Patients with dermatomyositis have faced a significant unmet need for effective treatments," said Nikolay Nikolov, director of the Office of Immunology and Inflammation in the FDA's Center for Drug Evaluation and Research, in the agency's announcement. He described patients as often relying on therapies meant for other diseases.
Inside the Trial Behind the Approval
The approval rests on a Phase 3 randomized, double-blind, multicenter, placebo-controlled study of 241 adults, registered under the identifier NCT05437263 and known as VALOR. Participants received brepocitinib 30 mg once daily, brepocitinib 15 mg once daily or placebo across a 52-week treatment period. The manufacturer describes it as the largest dermatomyositis trial ever conducted.
The trial's primary measure was the myositis Total Improvement Score at week 52, a composite tool that tracks change across six domains: muscle strength, physical function, skin and other disease activity, muscle enzymes, and both physician and patient assessments of overall health. Participants on the 30 mg dose achieved a higher average score than those on placebo and showed improvements in physical function and skin disease activity.
Context matters here. An improvement in composite score is not the same as a cure, and 241 participants is a substantial trial for a rare disease but a small one in absolute terms. Primary results were published in the New England Journal of Medicine in March, with skin-specific trial outcomes published in JAMA Dermatology this month, indicating that the underlying data have undergone peer review rather than existing only in company materials.
Steroid Tapering Is the Result Patients Notice Most
The finding most likely to change daily life is the steroid data. In the manufacturer's announcement of the approval, Priovant Therapeutics reported that 55 percent of treated patients achieved both moderate or better improvement and minimal or no steroid use by the end of the study, compared with 30 percent in the placebo group.
Among patients taking at least 7.5 mg per day of oral corticosteroids at baseline, 62 percent tapered to minimal or no steroid use by week 52, compared with 38 percent on placebo, and 45 percent came off corticosteroids entirely, compared with 29 percent.
Anyone who has taken long-term prednisone understands why that matters. Chronic steroids carry bone loss, weight gain, elevated blood sugar, cataracts, infection risk, and mood effects. A therapy that allows a substantial share of patients to get off them addresses a burden separate from the disease itself.
Ruth Ann Vleugels, a professor of dermatology at Harvard Medical School who was quoted in the company announcement, said that "the approval of Lisraya marks a turning point for patients living with dermatomyositis."These figures come from the company and should be read as such, though they align with the FDA's own statement that treated participants were more likely to reduce corticosteroid use by week 48.
A Boxed Warning That Shapes Who Should Take It
Lisraya carries the FDA's most serious warning label. The boxed warning covers serious infections, increased all-cause mortality, malignancies, major adverse cardiovascular events, and thrombosis, risks associated with the JAK inhibitor class.
The specifics deserve a plain description. Patients face increased risk of serious bacterial, fungal, viral, and opportunistic infections that can lead to hospitalization or death, and must be evaluated and tested for tuberculosis before and during treatment. Higher rates of death, major cardiovascular events and blood clots have been observed with another JAK inhibitor in rheumatoid arthritis patients aged 50 and older who had at least one cardiovascular risk factor, and a higher rate of malignancies was observed in that same comparison. Current and former smokers carry additional risk for malignancy and cardiovascular events.
The drug is not recommended in severe liver or kidney impairment, is contraindicated in people with known hypersensitivity to it, and may cause fetal harm based on animal studies. Live vaccines should be avoided during treatment, and immunizations should be up to date beforehand. Gastrointestinal perforation and hypoglycemia in patients with diabetes also appear in the warnings.
The most common adverse reactions included upper respiratory tract infection, headache, fatigue, urinary tract infection, and nausea. Discontinuation due to adverse reactions occurred in 6 percent of patients on the 30 mg dose compared with 11 percent on placebo.
None of this makes the drug unsuitable. It makes the prescribing conversation a real one, particularly for older patients, smokers, and anyone with cardiovascular history. This article provides general information and is not a treatment recommendation; no patient should stop or change their existing therapy without speaking with their clinician.
Cost, Pharmacy Access, and the Road Ahead
The drug is available immediately through a limited distribution network of specialty pharmacies rather than retail counters, which typically means longer setup and more paperwork. Priovant says eligible patients may pay as little as zero dollars per month through its My Compass Support program, which offers help with insurance coverage and financial assistance. The announcement did not include a list price.
For a rare disease drug, the gap between an assistance program and actual coverage is where patients usually get stuck. Prior authorization is likely, and denials are appealable. Patients should ask their rheumatologist or dermatologist's office who handles the enrollment paperwork before assuming a prescription will simply be filled.
Several things remain unknown. Long-term safety beyond 52 weeks has not been established. There is no data supporting use in children, since the approval covers adults only. The drug is not recommended for use in combination with other JAK inhibitors, other TYK2 inhibitors, or biologic DMARDs. And how quickly insurers add it to formularies is unresolved.
The FDA granted the drug orphan drug designation and priority review, the latter reserved for medicines that would offer significant improvements in treating a serious condition. For patients who have spent years on steroids and off-label immunosuppressants, this is a legitimate new option worth raising at the next specialist appointment, weighed honestly against a serious warning label.
Key Questions Answered
What is dermatomyositis? A rare autoimmune disease in which the immune system attacks muscle and skin, producing chronic inflammation, progressive muscle weakness, and distinctive rashes that can be painful and itchy.
What makes this approval a first? Lisraya is the first oral drug approved by the FDA with a specific indication for dermatomyositis. Previous treatment relied on corticosteroids and medications approved for other conditions.
How well did it work? Patients on the 30 mg dose showed greater average improvement on a composite disease score at 52 weeks than placebo, along with better physical function and skin disease activity, and were more likely to reduce steroid use.
What are the safety risks? The drug carries a boxed warning for serious infections, increased all-cause mortality, malignancies, major adverse cardiovascular events, and thrombosis. Tuberculosis testing is required before and during treatment.
Who should be especially cautious? Adults 50 and older with cardiovascular risk factors, current and former smokers, people with active infections, and anyone with severe liver or kidney impairment. It may cause fetal harm.
What will it cost? The manufacturer has not published a list price. Eligible patients may pay as little as $0 per month through the company's support program, though prior authorization is likely required.
Is it approved for children? No. The approval covers adults only.
